肿瘤核素反义显像技术的研究现状与展望

秦光明

肿瘤核素反义显像技术的研究现状与展望

秦光明

文章导航 > 国际放射医学核医学杂志 > 2001, 25 > 5: (213-216)

引用本文:

Citation:

肿瘤核素反义显像技术的研究现状与展望

秦光明

430022 湖北武汉, 华中科技大学同济医学院协和医院核医学科

作者简介: 秦光明(1972-),男,湖北鄂州人,华中科技大学附属协和医院核医学科医师,硕士,主要研究肿瘤反义显像。;

基金项目:
湖北省科委课题基金
中图分类号: R817.4

Current researches and prospective of radiolabeled antisense imaging in tumor

QIN Guang-ming

Department of Nuclear Medicine, Union Hospital Tongji Medical University, Wuhan Hubei 430022, China
CLC number: R817.4

摘要: 反义显像具有不引起免疫反应、探针分子小、易进入瘤组织等优点,具有广阔的应用前景,但靶序列的选择、理想寡核苷酸的确定等仍是现阶段制约其发展的重要因素。因此,将反义显像引入体内研究还有很多问题需要解决,包括如何提高探针的体内稳定性、增加靶细胞的选择性摄取和滞留、降低血清蛋白非特异性结合等。
- 反义显像 /
- 肿瘤诊断 /
- 寡聚核苷酸 /
- 癌基因 /
- 放射性核素
Abstract: Radiolabeled antisense imaging may be defined as the detection of diseases through the administration of radiolabeled antisense oligonucleotide designed to bind in a sequence-specific manner to the machinery of translation or transcription. No immunogenity, low molecular weight of probes and easily penetrating the tumor cells are some of it's good aspects.Despite its good prospective, factors as selection of targeted serial, identification of ideal oligonucleotides are still roadblocks in developing antisense imaging. Many problems must be solved before in vivo application of antisense imaging, among those including in vivo stability, specific absorption and retention by targeted cells, nonspecific serum binding, and so on.
- antisense imaging /
- tumor diagnose /
- oligonucleotide /
- oncogene /
- radionuclides
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Hnatowich DJ. Antisense and nuclear medicine[J]. J Nucl Med, 1999, 40:693-703.
[2]	Dewanjee MK, Abdol KG, Kapadvanjwala M, et al.Noninvasive imaging of c-myc oncogene messenger RNA with Indium-111-antisense probes in a mammary tumor-bearing mouse model[J]. J Nucl Med, 1994, 35:1054-1063.
[3]	Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-erbB2 oncogen mRNA of breast tumor in mouse model with In-111 labeled antisens oligonucleotide[J]. J Nucl Med, 1994, 35:65.
[4]	Urbain JC, Shore SK, Vekemans MC, et al. Scintigraphic imaging of oncogens with antisense probes:does it make sense?[J]. Eur J Nucl Med, 1995, 22:499-504.
[5]	Hnatowich DJ, Winnard P, Virzi F, et al. Technetium-99m labeling of DNA oligonucleotides[J]. J Nucl Med, 1995, 36:2306-2314.
[6]	Winnard P, Chang F, Rusckowski M, et al. Preparation and use of NHS-MAG3 for Technetium-99m labeling of DNA[J]. Nucl Med Biol, 1997, 24:425-432.
[7]	Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides[J]. Biochim Biophys Acta, 1999, 1489(1):53-68.
[8]	Diasio RB, Zhang R. Pharmacology of therapeutic oligonucleotides. Antisense[J]. Nucleic Acid Drug Dev, 1997, 7:239-243.
[9]	Mardirossian G, Lei K, Rusckowski M, et al. In vivo hybridization of Technitium-99m-labeled peptide nucleic acid(PNA)[J]. J Nucl Med, 1997, 38:907-913.
[10]	Lu xiao-ming, Fischman AJ, Jyawook SL, et al. Antisense DNA delivery in vivo:liver targeting by receptor-mediated uptake[J]. J Nucl Med, 1994, 35:269-275.
[11]	Dadon J, Blum HE. Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells[J]. Hepatology, 1996, 24:474-481.
[12]	De Oliveira MC, Boutet V, Fattal E, et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice[J]. Life Sci, 2000, 67(13):1625-1637.
[13]	David DFM, Wei Ai-qun. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes[J]. Leuk Res, 1996, 20:925-930.
[14]	Sczakiel G. Theoretical and experimental approaches to design effective antisense oligonucleotides[J].Front Biosci, 2000, 5:D194-D201.
[15]	Larsen HJ, Bentin T, Nielsen PE. Antisense properties of peptide nucleic acid[J]. Biochim Biophys Acta, 1999, 1489(1):159-166.
[16]	Lubrich B, Calker D, Peschka SR. Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes[J]. Eur J Biochem, 2000, 267(8):2432-2438.
[17]	Hu RH, Chu SH. Suppression of tumor necrosis factor secretion from white blood cells by synthetic antisense phosphorothioate oligodeoxynucleotides[J]. Int J Immunopharmacol, 2000, 22(6):445-452.

[1]	赵利军 , 刘彦仿 , 周前 . 反义显像技术在肿瘤诊断中的应用. 国际放射医学核医学杂志, 1996, 20(3): 121-123.
[2]	杨卫东 , 朱承谟 . 肿瘤反义显像技术中的若干问题. 国际放射医学核医学杂志, 1998, 22(6): 244-247.
[3]	陈立波 , 朱瑞森 . NIS在肿瘤核素基因显像与治疗中的应用研究. 国际放射医学核医学杂志, 2005, 29(2): 70-73.
[4]	欧晓红 . 放射性核素反义治疗. 国际放射医学核医学杂志, 2002, 26(6): 246-248.
[5]	赵晋华 , 林祥通 . 抑郁症的放射性核素脑血流灌注和脑受体显像研究进展. 国际放射医学核医学杂志, 1998, 22(2): 49-51.
[6]	任均田 , 林学颜 . 放射免疫显像与治疗的应用进展. 国际放射医学核医学杂志, 1995, 19(2): 57-59.
[7]	夏劲松 . 反义显像技术的研究进展. 国际放射医学核医学杂志, 2001, 25(2): 62-65.
[8]	万建美 , 范我 . 动脉粥样硬化斑块核素显像研究进展. 国际放射医学核医学杂志, 2007, 31(1): 17-20.
[9]	张佳佳 , 樊鑫 , 秦珊珊 , 余飞 . 基于深度学习的人工智能在肿瘤诊断中的应用进展. 国际放射医学核医学杂志, 2020, 44(1): 11-15. doi: 10.3760/cma.j.issn.1673-4114.2020.01.004
[10]	诸洪达 , 陆梅 , 朱昌寿 . 食入放射性核素所致内照射剂量研究现状及展望. 国际放射医学核医学杂志, 1998, 22(3): 130-133.

点击查看大图

计量

文章访问数: 1125
HTML全文浏览量: 122
PDF下载量: 3

肿瘤核素反义显像技术的研究现状与展望

秦光明

作者简介:秦光明(1972-),男,湖北鄂州人,华中科技大学附属协和医院核医学科医师,硕士,主要研究肿瘤反义显像。

430022 湖北武汉, 华中科技大学同济医学院协和医院核医学科

收稿日期: 2000-08-21

基金项目: 湖北省科委课题基金

关键词:

摘要: 反义显像具有不引起免疫反应、探针分子小、易进入瘤组织等优点,具有广阔的应用前景,但靶序列的选择、理想寡核苷酸的确定等仍是现阶段制约其发展的重要因素。因此,将反义显像引入体内研究还有很多问题需要解决,包括如何提高探针的体内稳定性、增加靶细胞的选择性摄取和滞留、降低血清蛋白非特异性结合等。